6月25日，雅培盘中上涨3.27%，报94.05美元/股，成交额1.96亿美元。
消息面上，雅培与ALZpath签署全球许可协议，将ALZpath专有的磷酸化Tau 217抗体纳入阿尔茨海默病体外诊断测试的开发中。该合作旨在利用血液检测手段推进阿尔茨海默病的早期诊断，属于雅培诊断业务板块的重要战略布局。此前雅培已完成对Exact Sciences约210亿美元的收购以强化诊断业务，此次与ALZpath的合作进一步拓展了其在神经退行性疾病诊断领域的产品管线。
雅培公司主要业务为研究、开发、制造及销售保健品，拥有既有药品、诊断产品、营养产品和医疗器械四个可报告部门。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.